Clinical trial
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients…
NCT00479167 · Rush University Medical Center, Other · Terminated
Key facts
| NCT number | NCT00479167 |
|---|---|
| Title | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg |
| Lead sponsor | Rush University Medical Center, Other |
| Collaborators | GlaxoSmithKline Industry Millennium Pharmaceuticals, Inc. |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Follicular Lymphoma |
| Intervention type | Drug |
| Interventions | Bortezomib and Tositumomab I-131 |
| Enrollment | 1 |
| Start date | May 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | May 28, 2007 |
| Last update posted | Nov 4, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: